- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07771023
Effects of Exercise in Patients With Repaired Coarctation of the Aorta (KOREKT)
Effects of Exercise on Select Indicators of Cardiovascular Health in Patients With Repaired Coarctation of the Aorta
This interventional study will investigate the effects of high-intensity interval training (HIIT) in adults with repaired coarctation of the aorta. Participants will be randomised into three groups: HIIT performed at home, HIIT performed in a supervised outpatient setting, or a control group receiving usual care. The two HIIT protocols will be identical in intensity and progression, individually prescribed for each patient.
The study will evaluate the effects of HIIT on exercise capacity, health-related quality of life, blood pressure response to exercise, and other select measures of cardiovascular health, including vascular stiffness and endothelial function. In addition, the study will examine the acute effects of a single exercise session on arterial stiffness.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Ljubljana, Eslovênia, 1000
- University Medical Centre Ljubljana
-
Maribor, Eslovênia, 2000
- University Medical Centre Maribor
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- surgically repaired coarctation of the aorta,
- age at least 18 years, and
- signed informed consent form.
Exclusion Criteria:
- residual aortic stenosis (gradient across the narrowing >20 mmHg),
- presence of ascending aortic aneurysm,
- recent major cardiovascular event or other event requiring hospitalization (event less than 2 months before inclusion),
- unstable rhythm disturbances,
- unstable or low-threshold angina pectoris,
- NYHA class III or IV heart failure, and
- pregnancy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Outpatient HIIT
Anticipated number of patients: 15. Participants will complete a structured high-intensity interval training (HIIT) programme performed in an outpatient setting. Intensity and progression are identical to the home-based HIIT arm. |
A structured exercise programme performed under direct supervision in an outpatient/clinical setting on a stationary bicycle or treadmill, consisting of 36 one-hour sessions over 2-4 months (approximately 2-3 sessions per week). Each session will comprise 8 five-minute intervals, each consisting of 2 minutes at 85-95% of the heart rate reached at VO2peak, followed by 3 minutes of active recovery. The interval block will be preceded by a 5-minute active warm-up and followed by a 5-minute active cool-down. Interval intensity will be individually determined for each patient. |
|
Experimental: Home-based HIIT
Anticipated number of patients: 15. Participants will complete a structured high-intensity interval training (HIIT) programme performed independently at home. Intensity and progression are identical to the outpatient HIIT arm. |
A structured exercise programme performed independently at home, consisting of 36 one-hour sessions over 2-4 months (approximately 2-3 sessions per week). Each session will comprise 8 five-minute intervals, each consisting of 2 minutes at 85-95% of the heart rate reached at VO2peak, followed by 3 minutes of active recovery. The interval block will be preceded by a 5-minute active warm-up and followed by a 5-minute active cool-down. Interval intensity will be individually determined for each patient. |
|
Sem intervenção: Control (usual care)
Anticipated number of patients: 15. Participants will receive usual care, consisting of general counselling on physical activity performed at home, without a structured or supervised exercise training programme. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
VO2peak on cardiopulmonary exercise testing (CPET)
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Hypothesis: The outpatient high-intensity interval training (HIIT) programme improves aerobic capacity (measured by VO2peak) more than a home-based HIIT program or usual care.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Health-related quality of life
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Hypothesis: The outpatient high-intensity interval training (HIIT) programme improves health-related quality of life, assessed using the standardised SF-36 and EQ-5D questionnaires, more than a home-based HIIT programme or usual care.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Ratio of peak systolic blood pressure to peak workload (mmHg/W) on CPET
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Hypothesis: The outpatient high-intensity interval training (HIIT) programme reduces the ratio between peak systolic blood pressure and peak workload achieved during exercise testing more than a home-based HIIT programme or usual care.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean 24-hour systolic blood pressure
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of average systolic pressure during sleep and wakefulness, measured using 24-hour ambulatory blood pressure monitoring.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Echocardiographic parameters
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of standard echocardiographic measures of cardiac structure and function, including left ventricular global longitudinal strain (GLS).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Endothelial function of the right radial artery (flow-mediated dilation, FMD)
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Ultrasound assessment of endothelial function of the right radial artery, measured by flow-mediated dilation (FMD).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Heart rate variability
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of heart rate variability using high-resolution electrocardiography.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Biomarkers associated with vascular stiffness and atherosclerosis
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of circulating biomarkers associated with vascular stiffness and atherosclerosis, including atrial natriuretic peptide (ANP), growth/differentiation factor 15 (GDF-15), matrix metalloproteinase 1 (MMP-1), interleukin-33 receptor (IL-33/ST2), brain-derived neurotrophic factor (BDNF), galectin-3, myeloperoxidase, and tissue inhibitor of metalloproteinase 1 (TIMP-1).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Self-reported physical activity
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Self-reported physical activity level, assessed using the standardised International Physical Activity Questionnaire (IPAQ).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Body composition
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of body composition using bioelectrical impedance analysis.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Standard laboratory panel
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of standard laboratory parameters: electrolytes, renal function markers, liver function tests.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
NT-proBNP
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of NT-proBNP
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Extended lipid panel
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment extended lipid panel, including Lp(a).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Thyroid hormone level
Prazo: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of thyroid hormones.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 0120-101/2025-2711-4
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .